U.S. Senator Calls for CMS Probe of 12,400% Drug Price Hike

"We are committed to making Colcrys accessible to everyone who can benefit from it," Richard H. Roberts, MD, president/CEO of URL Pharma said in the February statement. "In response to feedback from patients and healthcare providers, we enhanced our Co-Pay Program to facilitate access to Colcrys."

URL Pharma reiterated its "very generous patient assistance efforts" in Tuesday's statement.

The pharmaceutical firm describes Colcrys as "the only single-ingredient colchicine product approved by the FDA, and is indicated for the prevention and treatment of gout flares and for the treatment of Familial Mediterranean Fever."

Brown's letters to URL Pharma and CMS can be viewed here and here, respectively. URL Pharma's statement may be viewed here.